| oxaliplatin / Generic mfg. |
NCT00040820: Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer |
|
|
| Completed | N/A | | US | oxaliplatin | Roswell Park Cancer Institute | Colorectal Cancer | 08/03 | 03/04 | | |
NCT00250029: Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen |
|
|
| Completed | N/A | 30 | US | Oxaliplatin, XELOX (oxaplatin+capecitabine) | New Mexico Cancer Care Alliance | Colonic Diseases, Cancer | 09/05 | 03/06 | | |
NCT01310972: Adjuvant Colon Cancer w/ ELOXatin®/5 FU Based Regimen: ACCELOX |
|
|
| Completed | N/A | 6 | RoW | Registry | King Faisal Specialist Hospital & Research Center | Colon Cancer | 09/07 | 09/07 | | |
NCT00039611: Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer |
|
|
| Completed | N/A | | US | FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin | National Cancer Institute (NCI) | Colorectal Cancer | | 10/07 | | |
NCT00897819: Studying DNA and Outcome in Patients With Advanced Colorectal Cancer Treated With Fluorouracil and Oxaliplatin With or Without Bevacizumab on Clinial Trial E-3200 |
|
|
| Completed | N/A | 350 | NA | DNA methylation analysis, loss of heterozygosity analysis, microsatellite instability analysis, laboratory biomarker analysis | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) | Colorectal Cancer | 01/08 | 01/08 | | |
NCT00729677: Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin |
|
|
| Completed | N/A | 64 | US | | Beth Israel Medical Center | Colorectal Cancer, Nausea, Vomiting | 11/08 | 12/08 | | |
NCT00131586: Cisplatin, Carboplatin, and Oxaliplatin Interactions With Plasma Proteins |
|
|
| Terminated | N/A | 100 | Canada | | AHS Cancer Control Alberta | Lung Cancer, Colorectal Cancer | 02/09 | 02/09 | | |
| Completed | N/A | 26 | Europe | | University of Oxford, oxBRC, Vodafone UK Foundation, Centre for Statistics in Medicine, Oncology Clinical Trials Office (OCTO, Oxford) | Metastatic Colorectal Cancer, Metastatic Breast Cancer | 12/10 | 04/11 | | |
NCT00826800: Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer |
|
|
| Terminated | N/A | 2 | US | FOLFOX and bevacizumab | Memorial Sloan Kettering Cancer Center, Genentech, Inc. | Colon Cancer | 01/11 | 01/11 | | |
NCT01437618: First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer |
|
|
| Completed | N/A | 15 | Europe | FOLFOXIRI plus bevacizumab | Azienda Ospedaliero, Universitaria Pisana | Metastatic Colorectal Cancer | | 05/11 | | |
|
NCT01339832: An Observational Study of Xeloda (Capecitabine) and Oxaliplatin Prior and Concurrent To Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer |
|
|
| Completed | N/A | 51 | Europe | | Hoffmann-La Roche, Sanofi | Colorectal Cancer | 12/11 | 12/11 | | |
NCT01134666: An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer |
|
|
| Terminated | N/A | 165 | RoW | Cetuximab, Erbitux | Merck KGaA, Darmstadt, Germany, Merck Ltd., India | Colorectal Neoplasms | 07/13 | 08/14 | | |
NCT00462501: Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer |
|
|
| Completed | N/A | 35 | US | bevacizumab, fluorouracil, leucovorin calcium, oxaliplatin, conventional surgery, radiation therapy | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Genentech, Inc. | Colorectal Cancer | 02/14 | 02/14 | | |
NCT01399190: An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer |
|
|
| Completed | N/A | 68 | Europe | Bevacizumab, Avastin®, Capecitabine, Xeloda®, Oxaliplatin, Eloxatin™ | Hoffmann-La Roche | Colorectal Cancer | 02/14 | 02/14 | | |
NCT02312284: Observational Study on the Patients With Rectal Cancer |
|
|
| Completed | N/A | 3995 | RoW | | Chinese Academy of Medical Sciences | Rectal Cancer, Adjuvant Chemoradiotherapy, Neoadjuvant Chemoradiotherapy, Adjuvant Chemotherapy, Surgery | 11/14 | 11/14 | | |
NCT01801085: Nursing and Pharmacy Time for Delivering Xeloda® Versus 5-Fluoruracil Regimens |
|
|
| Terminated | N/A | 21 | RoW | | Vivian Wing Yan Lee, Hoffmann-La Roche, Queen Elizabeth Hospital, Hong Kong, Princess Margaret Hospital, Hong Kong | Colorectal Cancer | 12/14 | 12/14 | | |
NCT01442155: An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer |
|
|
| Completed | N/A | 74 | Europe | Capecitabine, Xeloda, Oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 04/15 | 04/15 | | |
SIRFLOX, NCT00724503: FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer |
|
|
| Completed | N/A | 530 | US, Europe, RoW | SIR-Spheres yttrium-90 microspheres, mFOLFOX6m + SIRT, SIR-Spheres Y-90 microspheres, Systemic chemotherapy (FOLFOX), mFOLFOX6 | Sirtex Medical | Colorectal Cancer, Colorectal Carcinoma, Liver Metastases | 05/15 | 05/15 | | |
|
|
|
|
NCT01596634: Bovine Lactoferrin in Reducing Taste Disturbances in Patients With Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy |
|
|
| Completed | N/A | 12 | US | questionnaire administration, quality-of-life assessment, quality of life assessment, laboratory biomarker analysis, bovine lactoferrin | Wake Forest University Health Sciences, National Cancer Institute (NCI) | Colorectal Cancer, Dysgeusia, Oral Complications of Chemotherapy | 08/15 | 10/15 | | |
ATOM ES, NCT01834014: Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases |
|
|
| Completed | N/A | 110 | Japan | Bevacizumab, Avastin, Cetuximab, Erbitux, L-OHP, Oxaliplatin, l-LV, Levofolinate, 5-FU, Fluorouracil | EPS Corporation | Liver Metastasis, Colorectal Cancer | 03/17 | 03/17 | | |
NCT01506167: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN) |
|
|
| Completed | N/A | 719 | Europe | Bevacizumab, Avastin®, Capecitabine/Oxaliplatin, Fluorouracil/Folinic Acid/Oxaliplatin, Capecitabine, Fluorouracil/Folinic Acid/Irinotecan, Fluorouracil +/- Folinic Acid | Hoffmann-La Roche | Colorectal Cancer | 03/17 | 03/17 | | |
NCT01163305: PET-CT and Circulating Tumor Cells in Colorectal Cancer |
|
|
| Completed | N/A | 84 | RoW | Chemotherapy | Chinese University of Hong Kong | Colorectal Cancer, Metastasis | 04/17 | 04/17 | | |
AVACONT, NCT02305615: An Observational Study of Continued Bevacizumab Plus Chemotherapy Until First Progression in Participants With Metastatic Colorectal Cancer (CRC) |
|
|
| Completed | N/A | 300 | Europe | Bevacizumab, Avastin, Chemotherapy | Hoffmann-La Roche | Colorectal Cancer | 12/17 | 12/17 | | |
